Medtronic plc (NYSE:MDT) Shares Acquired by Annis Gardner Whiting Capital Advisors LLC

Annis Gardner Whiting Capital Advisors LLC grew its holdings in Medtronic plc (NYSE:MDT) by 81.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,410 shares of the medical technology company’s stock after acquiring an additional 1,084 shares during the period. Annis Gardner Whiting Capital Advisors LLC’s holdings in Medtronic were worth $200,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of MDT. Signaturefd LLC grew its stake in shares of Medtronic by 7.3% in the third quarter. Signaturefd LLC now owns 15,600 shares of the medical technology company’s stock worth $1,222,000 after acquiring an additional 1,061 shares in the last quarter. Aspire Private Capital LLC grew its stake in shares of Medtronic by 22.1% in the third quarter. Aspire Private Capital LLC now owns 1,590 shares of the medical technology company’s stock worth $125,000 after acquiring an additional 288 shares in the last quarter. Regent Peak Wealth Advisors LLC grew its stake in shares of Medtronic by 1.5% in the third quarter. Regent Peak Wealth Advisors LLC now owns 25,287 shares of the medical technology company’s stock worth $1,981,000 after acquiring an additional 370 shares in the last quarter. NBC Securities Inc. acquired a new position in shares of Medtronic in the third quarter worth $3,128,000. Finally, Pinnacle Financial Partners Inc grew its stake in shares of Medtronic by 0.8% during the third quarter. Pinnacle Financial Partners Inc now owns 288,804 shares of the medical technology company’s stock worth $22,631,000 after purchasing an additional 2,335 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Insider Activity

In other news, EVP Michael Marinaro sold 854 shares of the company’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $83.14, for a total value of $71,001.56. Following the completion of the sale, the executive vice president now directly owns 27,925 shares of the company’s stock, valued at $2,321,684.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.30% of the company’s stock.

Medtronic Stock Performance

MDT traded down $3.22 on Thursday, reaching $82.54. The company had a trading volume of 5,104,658 shares, compared to its average volume of 6,103,117. Medtronic plc has a 1 year low of $68.84 and a 1 year high of $91.00. The stock has a market capitalization of $109.60 billion, a PE ratio of 26.66, a P/E/G ratio of 2.78 and a beta of 0.78. The company has a quick ratio of 1.71, a current ratio of 2.30 and a debt-to-equity ratio of 0.46. The stock has a 50-day moving average price of $82.90 and a 200-day moving average price of $82.62.

Medtronic (NYSE:MDT) last announced its earnings results on Thursday, May 23rd. The medical technology company reported $1.46 EPS for the quarter, beating analysts’ consensus estimates of $1.45 by $0.01. Medtronic had a net margin of 13.00% and a return on equity of 13.71%. The business had revenue of $8.59 billion during the quarter, compared to analysts’ expectations of $8.44 billion. During the same period in the prior year, the company earned $1.57 earnings per share. The business’s revenue was up .5% compared to the same quarter last year. As a group, research analysts forecast that Medtronic plc will post 5.2 EPS for the current fiscal year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 12th. Stockholders of record on Friday, June 28th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 3.39%. This is a boost from Medtronic’s previous quarterly dividend of $0.69. Medtronic’s dividend payout ratio is presently 87.90%.

Analyst Ratings Changes

A number of brokerages recently commented on MDT. Mizuho boosted their target price on shares of Medtronic from $95.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, February 21st. Truist Financial boosted their target price on shares of Medtronic from $87.00 to $90.00 and gave the stock a “hold” rating in a research note on Wednesday, February 21st. Royal Bank of Canada reiterated a “sector perform” rating and set a $92.00 target price on shares of Medtronic in a research note on Wednesday, February 21st. Finally, Oppenheimer boosted their target price on shares of Medtronic from $89.00 to $92.00 and gave the stock a “market perform” rating in a research note on Wednesday, February 21st. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $94.91.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.